Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196), through unit Shanghai Fosun Pharmaceutical, obtained approval from China's National Medical Products Administration to register its Polyethylene Glycol (3350) and Electrolytes Powder, according to a Hong Kong bourse filing published late Monday.
The drug is used for the treatment of faecal impacion in children from the age of 5 years.
The pharmaceutical company invested 2.62 million yuan into the research and development of the drug.